Literature DB >> 7969197

Competitive polymerase chain reaction for quantitating feline immunodeficiency virus load in infected cat tissues.

M Pistello1, S Menzo, M Giorgi, L Da Prato, G Cammarota, M Clementi, M Bendinelli.   

Abstract

To quantitate FIV provirus copy numbers present in tissue of infected cats, we have applied a competitive polymerase chain reaction (cPCR) recently described for HIV. The method consists in coamplifying a fixed amount of the DNA to be examined with graded copy numbers of a DNA competitor incorporating a short deletion and bearing the same primer recognition sequences. These conditions ensure almost identical thermodynamic and amplification efficiency for both template species but permit a prompt recognition of the two amplification products by gel electrophoresis. Since the amounts of the two amplicons are dependent on relative initial template concentrations, the number of FIV genomes in the sample can be calculated by densitometric analysis of the electrophoretic bands. After validation, the method has been applied to study the provirus loads in the tissues of cats infected with the Pisa-M2 isolate of FIV.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969197     DOI: 10.1006/mcpr.1994.1032

Source DB:  PubMed          Journal:  Mol Cell Probes        ISSN: 0890-8508            Impact factor:   2.365


  15 in total

Review 1.  Quantitative molecular analysis of virus expression and replication.

Authors:  M Clementi
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.

Authors:  J Richardson; A Moraillon; S Baud; A M Cuisinier; P Sonigo; G Pancino
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

Review 4.  Quantitative molecular methods in virology.

Authors:  M Clementi; S Menzo; A Manzin; P Bagnarelli
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; L Zaccaro; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.

Authors:  S Lombardi; C Garzelli; M Pistello; C Massi; D Matteucci; F Baldinotti; G Cammarota; L da Prato; P Bandecchi; F Tozzini
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

Review 7.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

8.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 9.  Feline immunodeficiency virus neuropathogenesis: from cats to calcium.

Authors:  Rick B Meeker
Journal:  J Neuroimmune Pharmacol       Date:  2006-11-28       Impact factor: 4.147

10.  Dynamics of viral and proviral loads of feline immunodeficiency virus within the feline central nervous system during the acute phase following intravenous infection.

Authors:  G Ryan; D Klein; E Knapp; M J Hosie; T Grimes; M J E M F Mabruk; O Jarrett; J J Callanan
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.